AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9862541 — intervention group
Group type: COMPARATOR
Intervention: Spinal cord‐injured persons
Number of subjects: 23
Study 7619664 — intervention group
Group type: EXPERIMENTAL
Intervention: desipramine 100 mg
Number of subjects: 6
Study 7619664 — intervention group
Group type: EXPERIMENTAL
Intervention: reboxetine 4 mg
Number of subjects: 6
Study 7619664 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 2228340 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (mean maintenance daily dose of 0.30 +/- 0.03 mg)
Number of subjects: 34
Study 2228340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 2228340 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 34
Study 154426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamethacin (100 mg b.i.d.)
Number of subjects: 525
Study 154426 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg b.i.d.)
Number of subjects: 525
Study 30573506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab 1.0 mg/kg once weekly for 4 weeks and biweekly thereafter
Number of subjects: 71
Study 30573506 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice of chemotherapy
Number of subjects: 71
Study 27028701 — intervention group
Group type: EXPERIMENTAL
Intervention: Free preventive checkup with a qualified doctor
Number of subjects: 0
Study 27028701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 25782428 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g soy flour (whole soy group)
Number of subjects: 270
Study 25782428 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g low-fat milk powder + 63 mg daidzein (daidzein group)
Number of subjects: 270
Study 25782428 — intervention group
Group type: COMPARATOR
Intervention: 40 g low-fat milk powder (active control group)
Number of subjects: 270
Study 23562197 — intervention group
Group type: EXPERIMENTAL
Intervention: MFNS + OXY3 (200 μg MFNS q.d. + 3 sprays/nostril of OXY 0.05%)
Number of subjects: 705
Study 23562197 — intervention group
Group type: EXPERIMENTAL
Intervention: MFNS + OXY1 (200 μg MFNS q.d. + 1 spray/nostril of OXY)
Number of subjects: 705
Study 23562197 — intervention group
Group type: EXPERIMENTAL
Intervention: OXY b.i.d.
Number of subjects: 705
Study 23562197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study 23562197 — intervention group
Group type: EXPERIMENTAL
Intervention: MFNS q.d.
Number of subjects: 705
Study 19491907 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative therapies
Number of subjects: 0
Study 19491907 — intervention group
Group type: COMPARATOR
Intervention: Report from a UK-based arthritis charity
Number of subjects: 0
Study 17711659 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcoronary ablation of septal hypertrophy (TASH)
Number of subjects: 23
Study 17711659 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber cardiac pacing (PM)
Number of subjects: 23
Study 15226336 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (HDPEB) 40 mg/m² on days 1 through 5
Number of subjects: 299
Study 15226336 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cisplatin (PEB) 20 mg/m² on days 1 through 5
Number of subjects: 299
Study 15226336 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (HDPEB)
Number of subjects: 299
Study 15226336 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cisplatin (PEB)
Number of subjects: 299
Study 11477498 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (1200 mg/day)
Number of subjects: 64
Study 11477498 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 9352990 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 19
Study 9352990 — intervention group
Group type: COMPARATOR
Intervention: Monophasic shocks
Number of subjects: 19
Study 8176150 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA consultation
Number of subjects: 3593
Study 8176150 — intervention group
Group type: COMPARATOR
Intervention: Usual care by the attending physician
Number of subjects: 3593
Study 3312225 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral carotid arterial stenoses greater than 50%
Number of subjects: 333
Study 3312225 — intervention group
Group type: COMPARATOR
Intervention: Less severe contralateral carotid arterial stenoses
Number of subjects: 333
Study 3312225 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of significant contralateral disease
Number of subjects: 333
Study 30084517 — intervention group
Group type: EXPERIMENTAL
Intervention: VBN+
Number of subjects: 100
Study 30084517 — intervention group
Group type: COMPARATOR
Intervention: VBN-
Number of subjects: 100
Study 27196121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (1 μg∙kg‐1)
Number of subjects: 81
Study 27196121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 25622776 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone and counseling
Number of subjects: 353
Study 22614545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (Bup-SR) for 8 weeks
Number of subjects: 248
Study 22614545 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 248
Study 20921084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenator with high-resistance and low-compliance (Group 1)
Number of subjects: 23
Study 20921084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenator with low-resistance and high-compliance (Group 2)
Number of subjects: 23
Study 20921084 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 23
Study 20921084 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-resistance oxygenator (Group 2)
Number of subjects: 23
Study 20921084 — intervention group
Group type: COMPARATOR
Intervention: Both oxygenators
Number of subjects: 23
Study 18349557 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 1-week triple therapy followed by omeprazole (20 mg, qd) for 3 weeks (group A)
Number of subjects: 28
Study 18349557 — intervention group
Group type: COMPARATOR
Intervention: Standard 1-week triple therapy only (group B)
Number of subjects: 28
Study 18349557 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg, qd) for 3 weeks followed by 1-week triple therapy (group C)
Number of subjects: 28
Study 17201236 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg
Number of subjects: 57
Study 17201236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 14696468 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose anticancer drugs (Group A, n = 40)
Number of subjects: 82
Study 14696468 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose anticancer drugs (Group B, n = 42)
Number of subjects: 82
Study 9876959 — intervention group
Group type: EXPERIMENTAL
Intervention: eptastigmine 15 mg t.i.d.
Number of subjects: 320
Study 9876959 — intervention group
Group type: EXPERIMENTAL
Intervention: eptastigmine 10 mg t.i.d.
Number of subjects: 320
Study 9876959 — intervention group
Group type: EXPERIMENTAL
Intervention: eptastigmine (both doses) in severely impaired patients (n=222)
Number of subjects: 320
Study 9876959 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 320
Study 7907054 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 tablets (n = 106)
Number of subjects: 209
Study 7907054 — intervention group
Group type: COMPARATOR
Intervention: Artificial rupture of membranes only (n = 103)
Number of subjects: 209
Study 2685984 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 138
Study 828848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Motrin)
Number of subjects: 78
Study 828848 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 78
Study 28324091 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 51596
Study 28324091 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 51596
Study 26698250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine with dexmedetomidine (group D)
Number of subjects: 52
Study 26698250 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine only (group P)
Number of subjects: 52
Study 23810264 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) plus feedback
Number of subjects: 0
Study 23810264 — intervention group
Group type: COMPARATOR
Intervention: Video information (VI)
Number of subjects: 0
Study 23810264 — intervention group
Group type: COMPARATOR
Intervention: Informational brochure (IB)
Number of subjects: 0
Study 19405015 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with infliximab (administered at weeks 4, 6, 10, and then every 6 weeks)
Number of subjects: 158
Study 19405015 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment with infliximab (administered at weeks 4, 6, 10 and then upon symptom recurrence)
Number of subjects: 158
Study 17316832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprodex (ciprofloxacin 0.3%/dexamethasone 0.1%) for 5 days post-operatively
Number of subjects: 200
Study 17316832 — intervention group
Group type: COMPARATOR
Intervention: No treatment for 5 days post-operatively
Number of subjects: 200
Study 17316832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprodex treatment
Number of subjects: 200
Study 15549681 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual /bi/ and audio /bi/‐visual /vi/ habituation in female infants
Number of subjects: 0
Study 15549681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatched audio /bi/‐visual /vi/ habituation in male infants
Number of subjects: 0
Study 15549681 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant /bi/‐/bi/ versus /vi/‐/vi/ displays testing
Number of subjects: 0
Study 11369837 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 14
Study 11369837 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 14
Study 9645872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (300 mg base weekly)
Number of subjects: 106
Study 9645872 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (0.5 mg base/kg daily)
Number of subjects: 106
Study 9645872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 7837323 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. Tramadol (1 mg/Kg)
Number of subjects: 60
Study 7837323 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (20 ml) - Control group
Number of subjects: 60
Study 7837323 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 2967164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms)
Number of subjects: 26
Study 2967164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 26
Study 2967164 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined beta‐agonist and anticholinergic preparation (fenoterol hydrobromide 200 micrograms and ipratropium bromide 80 micrograms)
Number of subjects: 26
Study 2967164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31533666 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass deworming with albendazole alongside school-based deworming
Number of subjects: 64
Study 31533666 — intervention group
Group type: COMPARATOR
Intervention: School-based targeted deworming with albendazole
Number of subjects: 64
Study 29187242 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cooling plus best medical treatment
Number of subjects: 800
Study 29187242 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 800
Study 26637673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless femoral component
Number of subjects: 120
Study 26637673 — intervention group
Group type: COMPARATOR
Intervention: Cemented femoral component
Number of subjects: 120
Study 23646840 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable binge drinker stereotypes
Number of subjects: 755
Study 23646840 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions geared at increasing self-focused attention
Number of subjects: 755
Study 21334442 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR) training
Number of subjects: 0
Study 21334442 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting period)
Number of subjects: 0
Study 19799020 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) treatment
Number of subjects: 78
Study 19799020 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional therapy only)
Number of subjects: 78
Study 16407007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopic laser endopyelotomy
Number of subjects: 40
Study 16407007 — intervention group
Group type: COMPARATOR
Intervention: Acucise endopyelotomy
Number of subjects: 40
Study 15581190 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperarticulation of vowels
Number of subjects: 0
Study 15581190 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification and rating of each stimulus
Number of subjects: 0
Study 11526772 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic marsupialisation of endometrial cyst and coagulation
Number of subjects: 20
Study 11526772 — intervention group
Group type: COMPARATOR
Intervention: Stripping of lining
Number of subjects: 20
Study 9425972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine (1.4 mg/kg in 40 mL)
Number of subjects: 16
Study 9425972 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 16
Study 8075912 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1168
Study 8075912 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1168
Study 3631787 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobehavioral Cognitive Status Examination (NCSE)
Number of subjects: 30
Study 3631787 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Capacity Screening Examination (CCSE)
Number of subjects: 30
Study 3631787 — intervention group
Group type: COMPARATOR
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 30
Study 31524780 — intervention group
Group type: EXPERIMENTAL
Intervention: CON + BFR
Number of subjects: 17
Study 31524780 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC + BFR
Number of subjects: 17
Study 31524780 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 17
Study 31524780 — intervention group
Group type: COMPARATOR
Intervention: ECC
Number of subjects: 17
Study 30043250 — intervention group
Group type: EXPERIMENTAL
Intervention: Item response theory (IRT) based approach
Number of subjects: 0
Study 30043250 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache scores at 4 h post-dose
Number of subjects: 0
Study 30043250 — intervention group
Group type: COMPARATOR
Intervention: Headache scores at 2 h post-dose
Number of subjects: 0
Study 26329035 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique video demonstration
Number of subjects: 100
Study 24364989 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor-mask wearing consultations
Number of subjects: 1030
Study 24364989 — intervention group
Group type: COMPARATOR
Intervention: Non-mask wearing consultations
Number of subjects: 1030
Study 21422729 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 307
Study 21422729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 17804774 — intervention group
Group type: EXPERIMENTAL
Intervention: RF 2000 device
Number of subjects: 100
Study 17804774 — intervention group
Group type: EXPERIMENTAL
Intervention: RF 3000 device
Number of subjects: 100
Study 17804774 — intervention group
Group type: EXPERIMENTAL
Intervention: RITA device
Number of subjects: 100
Study 17804774 — intervention group
Group type: EXPERIMENTAL
Intervention: Internally cooled electrode device
Number of subjects: 100
Study 15352918 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (80 mg)
Number of subjects: 12
Study 15352918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg)
Number of subjects: 12
Study 15352918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9440422 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 km/h speed change
Number of subjects: 42
Study 9440422 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 km/h speed change
Number of subjects: 42
Study 9440422 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 4 km/h and 8 km/h
Number of subjects: 42
Study 8304306 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine at 8:30 AM
Number of subjects: 16
Study 8304306 — intervention group
Group type: COMPARATOR
Intervention: 40 mg famotidine at 10 PM
Number of subjects: 16
Study 2724250 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/m2 oral weekly methotrexate (MTX)
Number of subjects: 46
Study 2724250 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/m2 oral weekly methotrexate (MTX)
Number of subjects: 46
Study 2724250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 2724250 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 46
Study 31345271 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for juvenile idiopathic arthritis (JIA) using the Early Diagnosis of Chronic Arthritis - 12 items (EDA-12) questionnaire.
Number of subjects: 5710
Study 31345271 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of JIA in the studied population.
Number of subjects: 5710
Study 29390150 — intervention group
Group type: EXPERIMENTAL
Intervention: RV1 (monovalent rotavirus vaccine)
Number of subjects: 0
Study 29390150 — intervention group
Group type: COMPARATOR
Intervention: No RV1 (unvaccinated nonsecretors)
Number of subjects: 0
Study 27451396 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined method (direct measurements of spilled blood, sucker bottle volumes, weighing of surgical towels and drapes)
Number of subjects: 156
Study 27451396 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin level calculation
Number of subjects: 156
Study 27451396 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon's estimation
Number of subjects: 156
Study 27451396 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiologists' estimation
Number of subjects: 156
Study 27451396 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment by anesthesiologists
Number of subjects: 156
Study 24675993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol lock therapy (E-Lock)
Number of subjects: 200
Study 24675993 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter-care (CCC)
Number of subjects: 200
Study 22521298 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention promoting healthy dietary habits and increasing physical activity through the IVAC pedagogy applied over 2 school years (2006-2008)
Number of subjects: 0
Study 22521298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20558502 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex (nabiximols)
Number of subjects: 666
Study 20558502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666
Study 18042505 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose salmon oil (1 g tid for 24 weeks)
Number of subjects: 58
Study 18042505 — intervention group
Group type: COMPARATOR
Intervention: Crossover to salmon oil treatment (from CT-SO to SO)
Number of subjects: 58
Study 18042505 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose salmon oil (3 g/day)
Number of subjects: 58
Study 17065044 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamins A 1000 IU, B6 2.2 mg, B12 2.2 microg, C 200 mg, E 400 IU, folic acid 400 microg, N-acetylcysteine 200 mg, Cu 2 mg, Zn 15 mg, Mn 0.5 mg, Fe 30 mg, calcium 800 mg, selenium 100 microg)
Number of subjects: 60
Study 17065044 — intervention group
Group type: COMPARATOR
Intervention: Control group (Fe 30 mg and folic acid 400 microg)
Number of subjects: 60
Study 17065044 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 60
Study 12562405 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment group (pressure-controlled stepwise increase in PEEP up to 15 cmH2O and tidal volumes of up to 18 ml x kg(‐1) for 10 cycles)
Number of subjects: 78
Study 12562405 — intervention group
Group type: COMPARATOR
Intervention: 5 PEEP (5 cmH2O of positive end-expiratory pressure applied after manual inflation)
Number of subjects: 78
Study 12562405 — intervention group
Group type: COMPARATOR
Intervention: No PEEP (standard post bypass manual lung inflation with no PEEP)
Number of subjects: 78
Study 10365012 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 1: Detection of an audible noise
Number of subjects: 80
Study 10365012 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 2: Detection of end-tidal carbon dioxide in the oral cavity
Number of subjects: 80
Study 10365012 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 3: Observation of the aneroid manometer dial as the pressure increased
Number of subjects: 80
Study 10365012 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 4: Detection of an audible noise by neck auscultation
Number of subjects: 80
Study 10365012 — intervention group
Group type: COMPARATOR
Intervention: Manometric stability test
Number of subjects: 80
Study 8713637 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Xylocaine 1 mg.Kg‐1 followed by Propofol 2 mg.Kg‐1 over 20 seconds
Number of subjects: 64
Study 8713637 — intervention group
Group type: COMPARATOR
Intervention: Group B: Xylocaine 1 mg.Kg‐1 and Fentanyl 1.5 ug.Kg‐1 followed by Propofol 2 mg.Kg‐1 over 20 seconds
Number of subjects: 64
Study 8713637 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A and Group B
Number of subjects: 64
Study 8713637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 ug.Kg‐1 with Propofol 2 mg.Kg‐1
Number of subjects: 64
Study 2051364 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable Partial Dentures (RPDs)
Number of subjects: 232